Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "Where To Buy Sedatives"

Looking for quality documents?
external link icon
Repligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference
WALTHAM, Mass., May 26, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that it will participate in the 13 th Annual Craig-Hallum Institutional Investor Conference being held on June 1 in Minneapolis, MN. This conference provides institutional investors the opportunity to meet with Company management and does not include a formal presentation. Repligen’s most recent investor presentation will be accessible through the Investor Events section of Company’s website.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A
external link icon
Repligen to Report Fourth Quarter and Full Year 2015 Financial Results
WALTHAM, Mass., Feb. 17, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report fourth quarter and full year 2015 financial results on Thursday, February 25, 2016. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the reporting period ended December 31, 2015. The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers and (404) 537-3372 for international callers. Participants must provide the passcode 41151742. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 41151742. About Repligen
external link icon
Repligen to Report Fourth Quarter and Fiscal Year 2013 Financial Results
WALTHAM, Mass., Feb. 25, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that it will report fourth quarter and fiscal year 2013 financial results on Thursday, March 6, 2014. The Company will issue a press release before the market opens and will host a conference call at 9:00 a.m. EST to discuss business updates and financial results for the reporting periods ended December 31, 2013. In addition, the Company will provide financial guidance for its fiscal year 2014. Repligen's fourth quarter conference call will be accessible by dialing (866) 318-8620 for domestic callers or (617) 399-5139 for international callers. Dial-in participants must provide the passcode 47036442. Alternatively, a webcast will be accessible via the Investor section of Repligen's website www.repligen.com . Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617)
external link icon
Repligen to Present at the 25th Annual Piper Jaffray Healthcare Conference
WALTHAM, Mass., Nov. 26, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the 25 th Annual Piper Jaffray Healthcare Conference on Tuesday, December 3 at 9:50 a.m. EST. The conference will be held December 3-4, 2013 at the New York Palace Hotel in New York. A live audio webcast of the Repligen presentation will be accessible through the Investor Relations section of Company's website at www.repligen.com ; see News & Events, Events & Presentations. This webcast will also be archived for a period of time on the Company's website. About Repligen Corporation Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies
external link icon
Repligen to Report Fourth Quarter and Full Year 2012 Financial Results
WALTHAM, Mass., March 1, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it will report financial results for the fourth quarter and year ended December 31, 2012 on March 7. On this date, the Company will issue a press release prior to the opening of the NASDAQ Global Market, followed by a conference call and webcast at 9:00 a.m. EST to discuss financial results for the reporting period. The event will be hosted by Walter C. Herlihy, Ph.D., President and CEO of Repligen. Repligen's fourth quarter and year end conference call will be accessible by dialing (800) 291-5365 for domestic callers or (617) 614-3922 for international callers. Dial-in participants must provide the passcode 66969032 . Alternatively, an audio webcast will be accessible via the Investors section of Repligen's website www.repligen.com . Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (888) 286-8010
external link icon
Repligen Licenses Rights to Use of HDAC3 Inhibitors for Memory Disorders
external link icon
Repligen Elects Glenn L. Cooper, M.D. to the Board of Directors
external link icon
Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
external link icon
Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors
corporate icon
KrosFlo® RS TFF Systems
The KrosFlo® RS are a series of tangential flow filtration (TFF) systems engineered for an era of new modalities. These systems are single-use and cGMP compliant with features like end-to-end automation, minimal hold-up volumes, and effortless scalability. Support automated ultrafiltration and diafiltration (UF/DF) processes for batch volume ranges of 35mL to 2000L.